Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 1
1947 1
1969 2
1976 4
1977 3
1978 2
1982 1
1983 2
1986 1
1991 1
1993 1
1994 2
1995 1
1996 1
1997 1
1999 2
2002 2
2004 1
2005 2
2007 5
2008 2
2009 4
2010 5
2011 6
2012 6
2013 4
2014 5
2015 5
2016 3
2017 4
2018 6
2019 5
2020 5
2021 3
2022 6
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

92 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial.
Russell S, Bennett J, Wellman JA, Chung DC, Yu ZF, Tillman A, Wittes J, Pappas J, Elci O, McCague S, Cross D, Marshall KA, Walshire J, Kehoe TL, Reichert H, Davis M, Raffini L, George LA, Hudson FP, Dingfield L, Zhu X, Haller JA, Sohn EH, Mahajan VB, Pfeifer W, Weckmann M, Johnson C, Gewaily D, Drack A, Stone E, Wachtel K, Simonelli F, Leroy BP, Wright JF, High KA, Maguire AM. Russell S, et al. Among authors: wellman ja. Lancet. 2017 Aug 26;390(10097):849-860. doi: 10.1016/S0140-6736(17)31868-8. Epub 2017 Jul 14. Lancet. 2017. PMID: 28712537 Free PMC article. Clinical Trial.
Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials.
Maguire AM, Russell S, Wellman JA, Chung DC, Yu ZF, Tillman A, Wittes J, Pappas J, Elci O, Marshall KA, McCague S, Reichert H, Davis M, Simonelli F, Leroy BP, Wright JF, High KA, Bennett J. Maguire AM, et al. Among authors: wellman ja. Ophthalmology. 2019 Sep;126(9):1273-1285. doi: 10.1016/j.ophtha.2019.06.017. Epub 2019 Jun 22. Ophthalmology. 2019. PMID: 31443789 Free article. Clinical Trial.
Genetic Medicine for Hearing Loss: OTOF as Exemplar.
Hickox AE, Valero MD, McLaughlin JT, Robinson GS, Wellman JA, McKenna MJ, Sewell WF, Simons EJ. Hickox AE, et al. Among authors: wellman ja. J Am Acad Audiol. 2021 Nov;32(10):646-653. doi: 10.1055/s-0041-1730410. Epub 2022 May 24. J Am Acad Audiol. 2021. PMID: 35609591 Review.
Assessing the state of Medicaid coverage for gene and cell therapies.
Berry D, Wellman J, Allen J, Mayer C. Berry D, et al. Among authors: wellman j. Mol Ther. 2022 Sep 7;30(9):2879-2880. doi: 10.1016/j.ymthe.2022.08.009. Epub 2022 Aug 26. Mol Ther. 2022. PMID: 36029768 Free PMC article. No abstract available.
92 results